Feedback / Questions
OT-A201 - Onward Therap
https://www.prnewswire.com/news-releases/onward-therapeutics-announces-enrollment-of-phase-1-clinical-trial-of-a-novel-bispecific-antibody-ot-a201-targeting-two-immune-checkpoints-302042048.html
Jan 24, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next